These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 24115322)

  • 1. Glucosylceramide mimics: highly potent GCase inhibitors and selective pharmacological chaperones for mutations associated with types 1 and 2 Gaucher disease.
    Schönemann W; Gallienne E; Ikeda-Obatake K; Asano N; Nakagawa S; Kato A; Adachi I; Górecki M; Frelek J; Martin OR
    ChemMedChem; 2013 Nov; 8(11):1805-17. PubMed ID: 24115322
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New insights into the pharmacological chaperone activity of c2-substituted glucoimidazoles for the treatment of Gaucher disease.
    Li Z; Li T; Dai S; Xie X; Ma X; Zhao W; Zhang W; Li J; Wang PG
    Chembiochem; 2013 Jul; 14(10):1239-47. PubMed ID: 23775891
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Polyhydroxylated bicyclic isoureas and guanidines are potent glucocerebrosidase inhibitors and nanomolar enzyme activity enhancers in Gaucher cells.
    Trapero A; Alfonso I; Butters TD; Llebaria A
    J Am Chem Soc; 2011 Apr; 133(14):5474-84. PubMed ID: 21413704
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hydrophilic iminosugar active-site-specific chaperones increase residual glucocerebrosidase activity in fibroblasts from Gaucher patients.
    Chang HH; Asano N; Ishii S; Ichikawa Y; Fan JQ
    FEBS J; 2006 Sep; 273(17):4082-92. PubMed ID: 16934036
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potent aminocyclitol glucocerebrosidase inhibitors are subnanomolar pharmacological chaperones for treating gaucher disease.
    Trapero A; González-Bulnes P; Butters TD; Llebaria A
    J Med Chem; 2012 May; 55(9):4479-88. PubMed ID: 22512696
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chaperone activity of bicyclic nojirimycin analogues for Gaucher mutations in comparison with N-(n-nonyl)deoxynojirimycin.
    Luan Z; Higaki K; Aguilar-Moncayo M; Ninomiya H; Ohno K; García-Moreno MI; Ortiz Mellet C; García Fernández JM; Suzuki Y
    Chembiochem; 2009 Nov; 10(17):2780-92. PubMed ID: 19830760
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rapid modifications of N-substitution in iminosugars: development of new β-glucocerebrosidase inhibitors and pharmacological chaperones for Gaucher disease.
    Cheng WC; Weng CY; Yun WY; Chang SY; Lin YC; Tsai FJ; Huang FY; Chen YR
    Bioorg Med Chem; 2013 Sep; 21(17):5021-8. PubMed ID: 23880081
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Selective chaperone effect of aminocyclitol derivatives on G202R and other mutant glucocerebrosidases causing Gaucher disease.
    Serra-Vinardell J; Díaz L; Gutiérrez-de Terán H; Sánchez-Ollé G; Bujons J; Michelakakis H; Mavridou I; Aerts JM; Delgado A; Grinberg D; Vilageliu L; Casas J
    Int J Biochem Cell Biol; 2014 Sep; 54():245-54. PubMed ID: 25084554
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel beta-glucocerebrosidase chaperone compounds identified from cell-based screening reduce pathologically accumulated glucosylsphingosine in iPS-derived neuronal cells.
    Naito Y; Sakamoto S; Kojima T; Homma M; Tanaka M; Matsui H
    SLAS Discov; 2023 Oct; 28(7):344-349. PubMed ID: 37369311
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The pharmacological chaperone isofagomine increases the activity of the Gaucher disease L444P mutant form of beta-glucosidase.
    Khanna R; Benjamin ER; Pellegrino L; Schilling A; Rigat BA; Soska R; Nafar H; Ranes BE; Feng J; Lun Y; Powe AC; Palling DJ; Wustman BA; Schiffmann R; Mahuran DJ; Lockhart DJ; Valenzano KJ
    FEBS J; 2010 Apr; 277(7):1618-38. PubMed ID: 20148966
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Probing the Inhibitor versus Chaperone Properties of sp²-Iminosugars towards Human β-Glucocerebrosidase: A Picomolar Chaperone for Gaucher Disease.
    Mena-Barragán T; García-Moreno MI; Sevšek A; Okazaki T; Nanba E; Higaki K; Martin NI; Pieters RJ; Fernández JMG; Mellet CO
    Molecules; 2018 Apr; 23(4):. PubMed ID: 29673163
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alpha-1-C-octyl-1-deoxynojirimycin as a pharmacological chaperone for Gaucher disease.
    Yu L; Ikeda K; Kato A; Adachi I; Godin G; Compain P; Martin O; Asano N
    Bioorg Med Chem; 2006 Dec; 14(23):7736-44. PubMed ID: 16919960
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bicyclic derivatives of L-idonojirimycin as pharmacological chaperones for neuronopathic forms of Gaucher disease.
    Alfonso P; Andreu V; Pino-Angeles A; Moya-García AA; García-Moreno MI; Rodríguez-Rey JC; Sánchez-Jiménez F; Pocoví M; Ortiz Mellet C; García Fernández JM; Giraldo P
    Chembiochem; 2013 May; 14(8):943-9. PubMed ID: 23606264
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glucocerebrosidase inhibitors for the treatment of Gaucher disease.
    Trapero A; Llebaria A
    Future Med Chem; 2013 Apr; 5(5):573-90. PubMed ID: 23573974
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Stereodivergent synthesis of right- and left-handed iminoxylitol heterodimers and monomers. Study of their impact on β-glucocerebrosidase activity.
    Stauffert F; Serra-Vinardell J; Gómez-Grau M; Michelakakis H; Mavridou I; Grinberg D; Vilageliu L; Casas J; Bodlenner A; Delgado A; Compain P
    Org Biomol Chem; 2017 May; 15(17):3681-3705. PubMed ID: 28401966
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Human Acid β-Glucosidase Inhibition by Carbohydrate Derived Iminosugars: Towards New Pharmacological Chaperones for Gaucher Disease.
    Parmeggiani C; Catarzi S; Matassini C; D'Adamio G; Morrone A; Goti A; Paoli P; Cardona F
    Chembiochem; 2015 Sep; 16(14):2054-64. PubMed ID: 26376302
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structure of acid beta-glucosidase with pharmacological chaperone provides insight into Gaucher disease.
    Lieberman RL; Wustman BA; Huertas P; Powe AC; Pine CW; Khanna R; Schlossmacher MG; Ringe D; Petsko GA
    Nat Chem Biol; 2007 Feb; 3(2):101-7. PubMed ID: 17187079
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Amphiphilic 1-deoxynojirimycin derivatives through click strategies for chemical chaperoning in N370S Gaucher cells.
    Diot JD; Garcia Moreno I; Twigg G; Ortiz Mellet C; Haupt K; Butters TD; Kovensky J; Gouin SG
    J Org Chem; 2011 Oct; 76(19):7757-68. PubMed ID: 21830816
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of GM1-Ganglioside Secondary Accumulation in Fibroblasts from Neuropathic Gaucher Patients and Effect of a Trivalent Trihydroxypiperidine Iminosugar Compound on Its Storage Reduction.
    Ceni C; Clemente F; Mangiavacchi F; Matassini C; Tonin R; Caciotti A; Feo F; Coviello D; Morrone A; Cardona F; Calamai M
    Molecules; 2024 Jan; 29(2):. PubMed ID: 38257371
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Promising results of the chaperone effect caused by imino sugars and aminocyclitol derivatives on mutant glucocerebrosidases causing Gaucher disease.
    Sánchez-Ollé G; Duque J; Egido-Gabás M; Casas J; Lluch M; Chabás A; Grinberg D; Vilageliu L
    Blood Cells Mol Dis; 2009; 42(2):159-66. PubMed ID: 19167250
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.